Why the study?
Gender-affirming hormone therapy has endocrine effects with potential cardiovascular consequences, but its effects on cardiac mechanics have yet to be characterized.
Does exogenous hormone therapy affect echocardiographic parameters of cardiac mechanics in altered hormonal states?
Does exogenous hormone therapy affect echocardiographic parameters of cardiac mechanics in altered hormonal states?
Hormonal changes within physiologic ranges do not appear to detrimentally affect echocardiographic parameters of systolic and diastolic function, though supraphysiologic testosterone may impair cardiac mechanics.
GAHT effects on cardiac mechanics uncharacterized; leaves open whether therapy alters strain or function in transgender patients.
Transgender individuals are increasingly seeking the care of physicians to physically transition to their self-identified gender identity. Gender-affirming hormone therapy (GAHT) has significant endocrine effects which may have cardiovascular consequences, and cardiovascular disease in transgender individuals is a growing area of study. The effects of GAHT on cardiac mechanics have yet to be characterized, but there is existing literature regarding changes to cardiac mechanics in similar altered hormonal states. We reviewed this literature, with a focus on echocardiographic findings. We found variable results between studies of different methodologies. These include findings that supraphysiological levels of testosterone may impair cardiac mechanics, whereas estrogen-containing hormonal replacement therapy may improve diastolic echocardiographic parameters. In summary, there are alterations to echocardiographic parameters in altered endocrine states related to exogenous testosterone and estrogen, in a manner that is likely dose-dependent. Encouragingly, the studies we reviewed did not suggest that hormonal changes within physiologic ranges would detrimentally affect echocardiographic parameters of systolic and diastolic function. Future research into the cardiovascular effects of long-term GAHT is warranted to safely guide the longitudinal treatment of transgender individuals.
No takes yet. Share an insight, caveat, or question.
Moudgal et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: